Program

Chairs: Prof Rik Thompson – Queensland University of Technology, Australia; Dr Christine Gilles – Université de Liège, Belgium

Time (AEST, Brisbane)	Speaker	Title
14:00	Prof Jean Paul Thiery – BioCheetah Pte Ltd, Singapore	How to deal with the EMT phenotypes in carcinoma.
14:20	Dr Xin Ye – Genentech, USA	TraCe-seq as a Platform to Decode Drug Response Heterogeneity.
14:40	Assoc Prof Timothy Burns – University of Pittsburgh, USA	Targeting TWIST1 in Oncogene Driven Lung Cancer.
15:00	Prof Pilnam Kim – KAIST, South Korea	The mode and dynamics of glioblastoma cell invasion into a decellularized matrix-based 3D model.
15:20	Prof Jing Yang – University of California, USA	Targeting extracellular matrix mechanotransduction to control EMT states and inhibit carcinoma invasion.
15:40	Dr Vincent Wenkai Xiang – 7G BioVentures, USA Dr Xin Ye – Genentech, USA	Panel Discussion

Chairs: Dr Myriam Polette – Université De Reims, France; Dr Pierre Savagner – Institut de Cancérologie Gustave Roussy, France

Time (AEST, Brisbane)	Speaker	Title
23:00	Assoc Prof Christine Chaffer – Garvan Institute of Medical Research, Australia	Targeting androgen signalling to prevent cell plasticity and sensitise triple-negative breast cancer to chemotherapy.
23:20	Prof Cédric Blanpain – Université Libre de Bruxelles, Belgium	Targeting EMT through pharmacological inhibition of Netrin-1 for cancer treatment.
23:40	Prof Patrick Mehlen – Netris Pharma, France	Netrin-1: a novel EMT modulator, from bench to Phase II clinical trial.
0:00	Assnt Prof Sid Puram – Washington University School of Medicine, USA	Hybrid EM states in head and neck cancer.
0:20	Assnt Prof Diwakar Pattabiraman – Geisel School of Medicine at Dartmouth, USA	Translating EMT state modulation to curb metastatic progression of breast cancers in the clinic.
0:40	Prof Patrick Mehlen – Netris Pharma, France Prof Cédric Blanpain – Université Libre de Bruxelles, Belgium Bob Weinberg – Whitehead Institute, MIT, USA	Panel Discussion

Chairs: Prof Jing Yang – University of California, USA; Assnt Prof Mohit Jolly – Indian Institute of Science, India

Time (AEST, Brisbane)	Speaker	Title
14:00	Prof Sendurai Mani – MD Anderson Cancer Center, USA	EMT, then and now.
14:20	Assnt Prof David Ting – Massachusetts General Hospital, USA	Pancreatic Cancer EMT Plasticity.
14:40	Prof Ruby Huang – National Taiwan University, Taiwan	Spatial profiling of intra-tumoral heterogeneity in epithelial-mesenchymal gradient.
15:00	Prof Shyamala Maheswaran – Harvard Medical School, USA	Epithelial to mesenchymal plasticity contributes to multi-faceted tumor diversity.
15:20	Assoc Prof Melissa Davis – Walter and Eliza Hall Institute, Australia	Capturing what we know about EMT in the Gene Ontology and other knowledge bases.
15:40	Prof Shyamala Maheswaran – Harvard Medical School, USA Dr Lara Perryman – Pharmaxis, Australia Anthony Williams – Curculogix, USA	Panel Discussion

Chairs: Guojun Sheng – Kumamoto University, Japan; Prof Ruby Huang – National Taiwan University, Taiwan

Time (AEST, Brisbane)	Speaker	Title
23:00	Assnt Professor Mohit Jolly – Indian Institute of Science, India	Immunosuppressive traits of the hybrid epithelial/mesenchymal phenotype.
23:20	Stéphane Terry – Institut de Cancérologie Gustave Roussy, France	Relationships between hypoxia, EMT and AXL in driving immune evasion of cancer.
23:40	Prof Geert Berx – CRIG, Ghent University, Belgium	Development and validation of a high-throughput screening pipeline of compound libraries to target EMT in malignant colorectal cancer.
0:00	Assnt Prof Min Yu – University of Southern California, USA	Hypoxic memory of type I interferon suppression in luminal breast cancer promotes metastasis.
0:20	Assnt Prof Anushka Dongre – Cornell University, USA	Sensitizing quasi-mesenchymal breast tumors to immune checkpoint blockade therapy by targeting CD73.
0:40	Mai-Jing Liao – RedCloud Bio, China Assnt Prof Anushka Dongre – Cornell University, USA	Panel Discussion

TBC = To Be Confirmed

Program Outline